NLS Pharmaceutics AG (NLSP)

NLS Pharmaceutics AG Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1.67	0.9	8.95	5.43	0.09
Cash & Short-Term Investments	1.67	0.9	8.95	5.43	0.09
Cash Growth	85.52%	-89.97%	64.76%	5695.69%	-57.46%
Other Receivables	-	0.04	0.04	0.04	0.06
Receivables	-	0.04	0.04	0.04	0.06
Prepaid Expenses	0.56	0.07	0.19	0.22	0.01
Other Current Assets	-	0.82	0.07	0.04	0.03
Total Current Assets	2.23	1.82	9.25	5.72	0.2
Property, Plant & Equipment	0.01	0.01	0.02	0.03	-
Long-Term Deferred Charges	-	-	-	-	0.95
Other Long-Term Assets	0	0.02	0.01	0.01	0.07
Total Assets	2.23	1.85	9.28	5.76	1.21
Accounts Payable	0.52	4.63	2.37	1.74	4.01
Accrued Expenses	0.31	1.54	0.97	0.65	1.25
Short-Term Debt	-	1.63	-	-	1.16
Current Portion of Long-Term Debt	-	-	-	-	0.61
Other Current Liabilities	-	0.11	0.01	0.02	0.18
Total Current Liabilities	0.83	7.92	3.36	2.4	7.2
Long-Term Debt	-	-	-	-	0.31
Long-Term Unearned Revenue	-	2.5	2.5	2.5	2.5
Total Liabilities	0.83	10.68	6	5.22	10.2
Common Stock	0.17	0.73	0.67	0.34	0.15
Additional Paid-In Capital	72.82	61.03	60.86	42.08	20.65
Retained Earnings	-74.43	-70.37	-58.2	-41.71	-29.76
Treasury Stock	-	-0.06	-	-0.03	-
Comprehensive Income & Other	0.11	-0.16	-0.05	-0.15	-0.02
Total Common Equity	-1.33	-8.83	3.28	0.54	-8.98
Shareholders' Equity	1.41	-8.83	3.28	0.54	-8.98
Total Liabilities & Equity	2.23	1.85	9.28	5.76	1.21
Total Debt	-	1.63	-	-	2.08
Net Cash (Debt)	1.67	-0.74	8.95	5.43	-1.99
Net Cash Growth	-	-	64.76%	-	-
Net Cash Per Share	1.08	-0.77	18.19	18.25	-11.44
Filing Date Shares Outstanding	3.16	1	0.81	0.37	0.3
Total Common Shares Outstanding	3.16	0.81	0.81	0.37	0.17
Working Capital	1.4	-6.1	5.89	3.32	-7.01
Book Value Per Share	-0.42	-10.90	4.05	1.47	-51.63
Tangible Book Value	-1.33	-8.83	3.28	0.54	-8.98
Tangible Book Value Per Share	-0.42	-10.90	4.05	1.47	-51.63
Machinery	-	0.01	0.01	0.01	-

Updated Oct 18, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q